2 completed, 2 not yet recruiting, 1 recruiting. 2 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Metastatic Invasive Breast Cancer: new trials by email Literature Review of Metastatic Invasive Breast Cancer trials Research Report on Metastatic Invasive Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy - Metastatic Invasive Breast Cancer, Resistant Breast Cancer | Phase 2 | Not yet recruiting | University of California, San Diego | 150 | 2027-07-01 | 2026-07-27 |
| Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer. Tumor assessment, Completion of Quality-of-life questionnaires, ECG - Metastatic Invasive Breast Cancer | Phase 3 | Not yet recruiting | UNICANCER | 370 | 2026-09-25 | 2026-07-21 |
| Diagnostic Prediction Model for De Novo Metastatic Breast Cancer Breast Cancer, Metastatic Invasive Breast Cancer | Recruiting | Markusovszky University Teaching Hospital os County Vas | 925 | 2026-08-10 | 2026-08-12 | |
| Promoting Active Living Among People With Advanced Cancer Acceptance- and mindfulness-based physical activity promotion - Metastatic Invasive Breast Cancer, Metastatic Invasive Gynecologic Cancer | Not applicable | Completed | University of Oklahoma | 36 | 2026-02-27 | 2026-10-20 |
| A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer Palbociclib, Bazedoxifene - Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 36 | 2015-07-09 | 2022-10-24 |
Breast Neoplasms (4)
Breast Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4)
Anastrozole (1) · Fulvestrant (1) · Tamoxifen (1) · bazedoxifene (1) · exemestane (1) · neratinib (1) · palbociclib (1)
Dana-Farber Cancer Institute (1) · Markusovszky University Teaching Hospital os County Vas (1) · UNICANCER (1) · University of California, San Diego (1) · University of Oklahoma (1)
United States (3) · Hungary (1)
Asona Lui, MD, PhD (1) · Michael C Robertson, MPH, PhD (1) · Rinath Jelsohn, MD (1)
2025 (1)